, Volume 176, Issue 3–4, pp 312–319 | Cite as

Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia

  • Lynne E. Rueter
  • Michael E. Ballard
  • Kelly B. Gallagher
  • Ana Maria Basso
  • Peter Curzon
  • Kathy L. Kohlhaas
Original Investigation



The rat neonatal ventral hippocampal (VH) ibotenic lesion model has been proposed as a developmental model of schizophrenia, based on evidence that it encompasses aspects of the disorder including psychomotor agitation (hyperactivity), deficits in prepulse inhibition (PPI), and deficits in social interaction (SI), measures presumed to reflect positive symptoms, sensory gating deficits and negative symptoms, respectively. However, validation of the model as a predictive pharmacological screening tool has been minimal.


Determine the effects of a chronic 3-week low dose treatment of clozapine or risperidone on locomotor hyperactivity, PPI and SI in lesioned and control rats.


Both clozapine, 2.5 mg/kg per day IP and risperidone, 0.1 mg/kg per day IP, reversed lesion-induced locomotor hyperactivity; however, the compounds also decreased locomotor activity in the non-lesioned controls. Clozapine 2.5 mg/kg per day and risperidone 0.1 mg/kg per day significantly attenuated lesion-induced PPI deficits. Neither compound induced a significant attenuation of lesion-induced SI deficits. In order to see if SI deficits required a higher dose of an antipsychotic, the dose of clozapine was increased to 4 mg/kg per day; however this dose induced such marked decreases in the activity and startle responses in the control rats, i.e. up to 74% decrease, that the effects on the lesioned rats could not be adequately interpreted.


These data add further support to the neonatal VH lesion model as a predictive pharmacological screening assay for identifying compounds effective in the treatment of positive symptoms of schizophrenia. However, the usefulness of the model in detecting compounds effective in treating negative symptoms of schizophrenia is still in question.


Locomotor hyperactivity Prepulse inhibition Social interaction Neurodevelopmental model Schizophrenia Antipsychotic 


  1. American Psychiatric Association (2000) Practice guidelines for the treatment of psychiatric disorder: compendium 2000. American Psychiatric Association, Washington D.C.Google Scholar
  2. Becker A, Grecksh G, Bernstein H-G, Höllt V, Bogerts B (1999) Social behavior in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144:333–338CrossRefPubMedGoogle Scholar
  3. Chambers RA, Moore J, McEvoy JP, Levin ED (1996) Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 15:587–594PubMedGoogle Scholar
  4. Harrison PJ (1999) The neuropathology of schizophrenia a critical review of the data and their interpretation. Brain 122:593–624CrossRefPubMedGoogle Scholar
  5. Joffe G, Venalainen E, Tupala J, Hiltunen O, Wahlbeck K, Gadeke R, Rimon R (1996) The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in out-patients. Int Clin Psychopharmacol 11:265–272PubMedGoogle Scholar
  6. Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503–517CrossRefGoogle Scholar
  7. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286–293Google Scholar
  8. Kapur S, Vanderspek SC, Brownlee BA, Nobriega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625–631CrossRefPubMedGoogle Scholar
  9. Kumari V, Soni W, Sharma T (1999) Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156:1046–1051PubMedGoogle Scholar
  10. Kumari V, Soni W, Sharma T (2002) Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 55:139–146CrossRefGoogle Scholar
  11. Le Pen G, Moreau J-L (2002) Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropscyhopharmacology 27:1–11CrossRefGoogle Scholar
  12. Lipska BK, Weinberger DR (1994) Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10:199–205PubMedGoogle Scholar
  13. Lipska BK, Weinberger DR (2000) To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23:223–239PubMedGoogle Scholar
  14. Lipska BK, Jaskiw GE, Weinberger DR (1993) Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9:67–75PubMedGoogle Scholar
  15. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995) Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122:35–43PubMedGoogle Scholar
  16. Pearlson GD (1999) New insights on the neuroanatomy of schizophrenia. Curr Psychiatr Rep 1:41–45PubMedGoogle Scholar
  17. Rowe WB, Spreekmeester E, Meaney MK, Quirion R, Rochford J (1998) Reactivity to novelty in cognitively-impaired and cognitively-unimpaired aged rats and young rats. Neuroscience 83:669–680CrossRefPubMedGoogle Scholar
  18. Sams-Dodd F, Lipska BK, Weinberger DR (1997) Neontal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 132:303–310CrossRefPubMedGoogle Scholar
  19. Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2002) Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159:255–262CrossRefPubMedGoogle Scholar
  20. Wilson WH (1996) Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 153:951–952PubMedGoogle Scholar
  21. Zhang W, Bymaster FP (1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5-HT2A and muscarinic receptors. Psychopharmacology 141:267–278Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Lynne E. Rueter
    • 1
  • Michael E. Ballard
    • 1
  • Kelly B. Gallagher
    • 1
  • Ana Maria Basso
    • 1
  • Peter Curzon
    • 1
  • Kathy L. Kohlhaas
    • 1
  1. 1.Neuroscience Research, R4N5 AP9AAbbott LaboratoriesAbbott ParkUSA

Personalised recommendations